Hemostemix Stock Current Valuation
| HEM Stock | CAD 0.08 0.01 11.11% |
Valuation analysis of Hemostemix helps investors to measure Hemostemix's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to climb to -4.85 in 2024. Enterprise Value Multiple is likely to climb to -4.85 in 2024. Fundamental drivers impacting Hemostemix's valuation include:
Price Book 27.7582 | Enterprise Value 15.1 M | Enterprise Value Ebitda (4.37) |
Overvalued
Today
Please note that Hemostemix's price fluctuation is out of control at this time. Calculation of the real value of Hemostemix is based on 3 months time horizon. Increasing Hemostemix's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Hemostemix stock is determined by what a typical buyer is willing to pay for full or partial control of Hemostemix. Since Hemostemix is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Hemostemix Stock. However, Hemostemix's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.08 | Real 0.0662 | Hype 0.07 | Naive 0.0823 |
The intrinsic value of Hemostemix's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Hemostemix's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Hemostemix helps investors to forecast how Hemostemix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Hemostemix more accurately as focusing exclusively on Hemostemix's fundamentals will not take into account other important factors: Hemostemix Company Current Valuation Analysis
Hemostemix's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Hemostemix Current Valuation | 15.05 M |
Most of Hemostemix's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hemostemix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Hemostemix Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Hemostemix is extremely important. It helps to project a fair market value of Hemostemix Stock properly, considering its historical fundamentals such as Current Valuation. Since Hemostemix's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Hemostemix's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Hemostemix's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Hemostemix has a Current Valuation of 15.05 M. This is 99.9% lower than that of the Biotechnology sector and 99.68% lower than that of the Health Care industry. The current valuation for all Canada stocks is 99.91% higher than that of the company.
Hemostemix Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hemostemix's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hemostemix could also be used in its relative valuation, which is a method of valuing Hemostemix by comparing valuation metrics of similar companies.Hemostemix is currently under evaluation in current valuation category among its peers.
Hemostemix Fundamentals
| Return On Asset | -3.49 | ||||
| Current Valuation | 15.05 M | ||||
| Shares Outstanding | 123.98 M | ||||
| Shares Owned By Insiders | 9.54 % | ||||
| Number Of Shares Shorted | 11.93 K | ||||
| Price To Earning | (1.70) X | ||||
| Price To Book | 27.76 X | ||||
| EBITDA | (2.16 M) | ||||
| Net Income | (2.5 M) | ||||
| Cash And Equivalents | 49.36 K | ||||
| Total Debt | 4.32 M | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (0.1) X | ||||
| Cash Flow From Operations | (1.5 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (0.02) X | ||||
| Target Price | 0.96 | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 11.16 M | ||||
| Total Asset | 313.76 K | ||||
| Retained Earnings | (63.27 M) | ||||
| Working Capital | (2.56 M) | ||||
| Net Asset | 313.76 K |
About Hemostemix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hemostemix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hemostemix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hemostemix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Hemostemix Stock Analysis
When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.